Circio Holding ASA (OSL:CRNA)
kr 0.724 0.016 (2.26%) Market Cap: 37.92 Mil Enterprise Value: 70.08 Mil PE Ratio: 0.98 PB Ratio: 0 GF Score: 1/100

Q4 2019 Targovax ASA Earnings Call Transcript

Mar 11, 2020 / 09:00AM GMT
Release Date Price: kr106.56 (-10.02%)
TorbjÃ;rn Furuseth
Targovax ASA - CFO

¸ -

Welcome, everybody. Welcome to the people in the room. Welcome to the people on the web. Welcome to the Fourth Quarter Presentation of Targovax. My name is Ãystein Soug, I'm the CEO. And with me today, I have Magnus Jäderberg, who is the Chief Medical Officer; and Torbjørn Furuseth, who is the CFO. I will give you an introduction and some highlights before Magnus will talk more about the trials and the recent data that we have achieved. And towards the end, Torbjørn will wrap up with the news flow and financials.

In cancer treatment, there's a revolution going on. And that revolution is immunotherapy. Within immunotherapies, the checkpoint inhibitors are leading this revolution, having a great impact on the treatment of patients today, even curing some patients and representing a market of $22 billion last year. But even though checkpoint inhibitors work really very well in some patients, they don't work well in all patients. Actually, most patients, they do not respond to checkpoint inhibitors. And in the indications where checkpoint

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot